Navigation Links
Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
Date:8/4/2009

PALO ALTO, Calif., August 4, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This technology, discovered in the lab of Stanford scientist and Eiger founder Dr. Jeffrey Glenn, M.D., Ph.D., is focused on a variety of novel targets, including key features of NS4B, a non-structural protein in the HCV genome, which binds to HCV-RNA and is required for viral replication.

"We are delighted to have licensed the rights to this exciting new technology from Stanford University," said David Cory, President and CEO of Eiger. "Disrupting the interaction between NS4B and HCV-RNA may be a promising new method to treat HCV infection and help combat drug resistance to HCV polymerase and protease inhibitors. We are rapidly advancing novel small molecule inhibitors of NS4B-RNA binding into the clinic for the benefit of clinicians and HCV patients."

"The unique two component nature of the NS4B-RNA target appears to decrease the virus' ability to escape inhibition by the small molecule inhibitors in development at Eiger, and that should decrease HCV resistance to this type of antiviral therapy," said Jeffrey Glenn. "These virus specific agents in development at Eiger possess the promise of more effective, oral drugs that can be essential components of all future cocktails for HCV therapy."

About Hepatitis C Virus

Infections from HCV have reached pandemic proportions, affecting over 150 million people worldwide. According to the Centers for Disease Control (CDC), 3.9 million Americans have been exposed to HCV, resulting in 2.7 million cases of chronic infection. Chronic HCV infection leads to serious liver disease (e.g. liver scarring and cirrhosis) and is the leading cause of liver cancer and liver transplantation in the U.S.

About Eiger BioPharmaceuticals, Inc.

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets for the treatment of hepatitis virus infections. Eiger's pipeline includes repurposed clinical stage therapeutic agents as well as preclinical NCEs from discovery that exhibit antiviral activity against Hepatitis C, Hepatitis D, and other viruses. Eiger www.eigerbio.com investors include InterWest Partners www.interwest.com and Vivo Ventures www.vivoventures.com.

    Contact:
    info@eigerbio.com
    1-650-320-9900


'/>"/>
SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Eiger BioPharmaceuticals Raises $7.1 Million A Round
2. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
3. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
5. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
6. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
7. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
9. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
10. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
11. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... ... ... Anton Paar USA, located in Ashland, Virginia is pleased to announce that construction ... a third office building to the current facilities. , Growth is nothing new. ... with office space adjacent to the previous main building. Through remodels and new construction, ...
(Date:5/19/2016)... 2016 - I dati saranno ... il 52 ° Congresso della ... - Le conclusioni dello studio indicano un tasso ... di cui il 90% presenta una d urata della ... Il settantadue per cento dei pazienti ha riscontrato un beneficio ...
(Date:5/18/2016)... ... May 18, 2016 , ... Every day, more than ... asthma complications.* Costing more than $56 billion in direct costs annually, asthma remains ... too many, the suffering associated with uncontrolled asthma can be overwhelmingly disproportionate and ...
(Date:5/17/2016)... Saudi Arabia (PRWEB) , ... May 17, 2016 ... ... the biopharmaceutical industry, and BioSmartSA, a healthcare consultancy based in Saudi Arabia, have ... of diagnostic services to healthcare providers in the Kingdom of Saudi Arabia (KSA). ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
Breaking Biology News(10 mins):